Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3013% below fair value
$8.32−0.18 (-2.12%)
Close on Nov 17, 2026Market cap $560.27MP/E –Yield –
Ginkgo Bioworks price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Ginkgo Bioworks's price to book ratio was 1.6× on Nov 11, 2026, against 0.9× a year earlier. Over the last 4 years it ranged from 0.4× to 28.6×, with a median of 1.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.6× | +0.7 |
| 2025 | Dec 31, 2025 | 0.8× | +0.2 |
| 2024 | Dec 31, 2024 | 0.7× | −0.7 |
| 2023 | Apr 28, 2023 | 1.3× | −0.6 |
| 2022 | Dec 30, 2022 | 1.9× | −6.0 |
| 2021 | Dec 31, 2021 | 8.0× | – |
See a number that looks wrong?